Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma
| Status: | Terminated |
|---|---|
| Conditions: | Blood Cancer, Hematology, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - 120 |
| Updated: | 11/18/2018 |
| Start Date: | October 2007 |
| End Date: | January 2010 |
A Pilot Study of Differentiation Therapy in Multiple Myeloma Using Interleukin-6 and Interferon-a
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-6 may
stimulate the white blood cells to kill cancer cells. Giving interferon alfa together with
interleukin-6 may kill more cancer cells.
PURPOSE: This clinical trial is studying the side effects and how well giving interferon alfa
together with interleukin-6 works in treating patients with recurrent multiple myeloma.
stimulate the white blood cells to kill cancer cells. Giving interferon alfa together with
interleukin-6 may kill more cancer cells.
PURPOSE: This clinical trial is studying the side effects and how well giving interferon alfa
together with interleukin-6 works in treating patients with recurrent multiple myeloma.
OBJECTIVES:
- Determine the response rate in patients with recurrent multiple myeloma treated with
recombinant interferon alfa and recombinant interleukin-6.
- Determine the safety and optimal dose of this regimen in these patients.
- Determine the toxicity of this regimen in these patients.
- Determine the impact of this regimen on clonogenic growth of myeloma cells in serial in
vitro assays.
OUTLINE: This is a pilot study.
Patients receive recombinant interferon alfa subcutaneously (SC) once daily. Beginning 1
month later, patients also receive recombinant interleukin-6 SC once daily. Treatment
continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study.
- Determine the response rate in patients with recurrent multiple myeloma treated with
recombinant interferon alfa and recombinant interleukin-6.
- Determine the safety and optimal dose of this regimen in these patients.
- Determine the toxicity of this regimen in these patients.
- Determine the impact of this regimen on clonogenic growth of myeloma cells in serial in
vitro assays.
OUTLINE: This is a pilot study.
Patients receive recombinant interferon alfa subcutaneously (SC) once daily. Beginning 1
month later, patients also receive recombinant interleukin-6 SC once daily. Treatment
continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study.
DISEASE CHARACTERISTICS:
- Diagnosis of recurrent multiple myeloma
- Must have received ≥ 2 prior therapies
PATIENT CHARACTERISTICS:
- Performance status 0-3
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
We found this trial at
1
site
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
Click here to add this to my saved trials
